In the second quarter of 2018, biopharma financing reached a total of $12.4 billion, a 25% decrease from the $16.6 billion raised during Q1. Dollar values in FOPOs and debt offerings were down compared with the previous quarter, but early-stage venture rounds made a strong showing in Q2. (See Exhibit 1.)
Biopharma Quarterly Dealmaking Statistics, Q2 2018
A look at financing, M&A and alliance activity April–June 2018
Biopharma financing for the second quarter totaled $12.4 billion, a 25% decrease from Q1 2018. Meanwhile Q2 merger and acquisition deal value reached $101 billion, three-quarters of which came from Takeda's $79 billion takeover of major European player Shire. Alliances – totaling $13.8 billion (a significant decline from the previous quarter's $30.7 billion) – featured large partnerships in the antibody space, the biotechnology industry sector with the highest dollar volume.
More from Deal-Making
More from In Vivo
• By
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
• By
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
• By
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.